Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers.
Magno G, Rejeski K, Rappa G, Stock S, Holzem A, Landwehr M, Seib M, Kutsch N, Mammadova J, Mayer S, Aumann S, Van Ham J, Ringelstein-Harlev S, Velazquez GF, Wurm-Kuczera R, Scholz JK, Greenbaum U, Raj SS, Shouval R, Müller F, Chapuy B, Schmid C, Beyar-Katz O, Vergote VK, Poeck H, Dong N, Holtick U, Ram R, Pabst T, Shumilov E, Lenz G, Iacoboni G, Barba P, Bücklein VL, Subklewe M.
Magno G, et al. Among authors: mammadova j.
Blood Adv. 2025 Oct 22:bloodadvances.2025017766. doi: 10.1182/bloodadvances.2025017766. Online ahead of print.
Blood Adv. 2025.
PMID: 41124666